McKesson Corporation (MCK) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $859.95 (-0.66%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 5, 2026 | Michael Cherny | Leerink Partners | $1085.00 | +26.2% |
| Jan 14, 2026 | Eric Coldwell | Robert W. Baird | $968.00 | +12.6% |
| Oct 27, 2025 | Kevin Caliendo | UBS | $920.00 | +7.0% |
| Aug 13, 2025 | Stephen Baxter | Wells Fargo | $772.00 | -10.2% |
| Jun 3, 2025 | Stephen Baxter | Wells Fargo | $766.00 | -10.9% |
| Nov 19, 2024 | Rob Dickerson | Jefferies | $715.00 | -16.9% |
| Nov 7, 2024 | Eric Coldwell | Robert W. Baird | $688.00 | -20.0% |
| Sep 25, 2024 | George Hill | Deutsche Bank | $579.00 | -32.7% |
| Sep 24, 2024 | Eric Coldwell | Robert W. Baird | $531.00 | -38.3% |
| Sep 13, 2024 | Stephen Baxter | Wells Fargo | $535.00 | -37.8% |
| Sep 6, 2024 | Michael Cherny | Leerink Partners | $665.00 | -22.7% |
| Sep 5, 2024 | Michael Cherny | Bank of America Securities | $635.00 | -26.2% |
| Aug 8, 2024 | Ann Hynes | Mizuho Securities | $570.00 | -33.7% |
| Jul 9, 2024 | Eric Coldwell | Robert W. Baird | $694.00 | -19.3% |
| Jun 24, 2024 | David Toung | Argus Research | $670.00 | -22.1% |
| May 29, 2024 | Eric Coldwell | Robert W. Baird | $679.00 | -21.0% |
| Apr 10, 2024 | David Toung | Argus Research | $570.00 | -33.7% |
| Apr 5, 2024 | Eric Coldwell | Robert W. Baird | $603.00 | -29.9% |
| Feb 8, 2024 | Eric Coldwell | Robert W. Baird | $567.00 | -34.1% |
| Feb 7, 2024 | Erin Wright | Morgan Stanley | $480.00 | -44.2% |
Top Analysts Covering MCK
MCK vs Sector & Market
| Metric | MCK | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.19 | 2.25 | 2.42 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +18.9% | +16366.1% | +18.0% |
| P/E Ratio | 22.35 | 2.99 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-03-31 | $438.97B | $443.00B | $446.67B | 12 |
| 2028-03-31 | $478.18B | $478.39B | $478.61B | 13 |
| 2028-06-30 | $122.17B | $124.21B | $125.67B | 1 |
| 2028-09-30 | $127.50B | $129.63B | $131.15B | 1 |
| 2028-12-31 | $129.96B | $132.12B | $133.68B | 1 |
| 2029-03-31 | $124.11B | $126.18B | $127.67B | 2 |
| 2029-06-30 | $131.00B | $133.19B | $134.75B | 2 |
| 2029-09-30 | $136.69B | $138.97B | $140.60B | 2 |
| 2029-12-31 | $139.32B | $141.64B | $143.31B | 2 |
| 2030-03-31 | $133.08B | $135.30B | $136.90B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-03-31 | $43.85 | $44.13 | $44.37 | 9 |
| 2028-03-31 | $49.01 | $49.97 | $51.36 | 3 |
| 2028-06-30 | $12.64 | $12.92 | $13.12 | 6 |
| 2028-09-30 | $12.78 | $13.06 | $13.26 | 5 |
| 2028-12-31 | $14.32 | $14.63 | $14.85 | 5 |
| 2029-03-31 | $15.49 | $15.83 | $16.07 | 4 |
| 2029-06-30 | $14.38 | $14.69 | $14.91 | 2 |
| 2029-09-30 | $14.54 | $14.86 | $15.09 | 2 |
| 2029-12-31 | $16.25 | $16.60 | $16.85 | 2 |
| 2030-03-31 | $17.60 | $17.98 | $18.26 | 2 |
Frequently Asked Questions
What is the analyst consensus for MCK?
The consensus among 16 analysts covering McKesson Corporation (MCK) is Buy with an average price target of $994.86.
What is the highest price target for MCK?
The highest price target for MCK is $1085.00, set by Michael Cherny at Leerink Partners on 2026-03-05.
What is the lowest price target for MCK?
The lowest price target for MCK is $257.00, set by Robert Jones at Goldman Sachs on 2021-05-07.
How many analysts cover MCK?
16 analysts have issued ratings for McKesson Corporation in the past 12 months.
Is MCK a buy or sell right now?
Based on 16 analyst ratings, MCK has a consensus rating of Buy (2.19/5) with a +18.9% upside to the consensus target of $994.86.
What are the earnings estimates for MCK?
Analysts estimate MCK will report EPS of $44.13 for the period ending 2027-03-31, with revenue estimated at $443.00B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.